| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4002293 | American Journal of Ophthalmology | 2013 | 10 Pages |
Abstract
Intravitreal 0.5 mg ranibizumab therapy improves retinal function, quantified not only by visual acuity, but also by mean retinal sensitivity and fixation stability, as assessed by scanning laser ophthalmoscope microperimetry. Measurement of retinal sensitivity may facilitate evaluation of the effectiveness of intravitreal ranibizumab treatment in patients with neovascular age-related macular degeneration.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Han Joo Cho, Chul Gu Kim, Su Jin Yoo, Sung Won Cho, Dong Won Lee, Jong Woo Kim, Joon H. Lee,